Skip to main content

Compare Stocks

Date Range: 

 4Front Ventures(CSI)1933 Industries28896AB Science
SymbolOTCMKTS:FFNTFCNSX:CSIOTCMKTS:TGIFFCNSX:BAMMOTCMKTS:ABSCF
Price Information
Current Price$1.28N/A$0.08N/A$17.14
52 Week RangeN/AN/AHoldN/ABuy
MarketRank™
Overall Score0.00.60.00.50.8
Analysis Score0.00.00.00.00.0
Community Score0.03.00.02.53.8
Dividend Score0.00.00.00.00.0
Ownership Score0.00.00.00.00.0
Earnings & Valuation Score0.00.00.00.00.0
Analyst Ratings
Consensus RecommendationN/AN/AHoldN/ABuy
Consensus Price TargetN/AN/AN/AN/AN/A
% Upside from Price TargetN/AN/AN/AN/AN/A
Trade Information
Market CapN/AN/AN/AN/AN/A
BetaN/AN/AN/AN/AN/A
Average Volume1,289,987N/A1,058,395N/A1,117
Sales & Book Value
Annual RevenueN/AN/AN/AN/AN/A
Price / SalesN/AN/AN/AN/AN/A
CashflowN/AN/AN/AN/AN/A
Price / CashN/AN/AN/AN/AN/A
Book ValueN/AN/AN/AN/AN/A
Price / BookN/AN/AN/AN/AN/A
Profitability
Net IncomeN/AN/AN/AN/AN/A
EPSN/AN/AN/AN/AN/A
Trailing P/E Ratio0.000.000.000.000.00
Forward P/E RatioN/AN/A
P/E GrowthN/AN/AN/AN/AN/A
Net MarginsN/AN/AN/AN/AN/A
Return on Equity (ROE)N/AN/AN/AN/AN/A
Return on Assets (ROA)N/AN/AN/AN/AN/A
Dividend
Annual PayoutN/AN/AN/AN/AN/A
Dividend YieldN/AN/AN/AN/AN/A
Three-Year Dividend GrowthN/AN/AN/AN/AN/A
Payout RatioN/AN/AN/AN/AN/A
Years of Consecutive Dividend GrowthN/AN/AN/AN/AN/A
Debt
Debt-to-Equity RatioN/AN/AN/AN/AN/A
Current RatioN/AN/AN/AN/AN/A
Quick RatioN/AN/AN/AN/AN/A
Ownership Information
Institutional Ownership PercentageN/AN/AN/AN/AN/A
Insider Ownership PercentageN/AN/AN/AN/AN/A
Miscellaneous
Employees380N/AN/A10193
Shares OutstandingN/AN/AN/AN/AN/A
Next Earnings DateN/AN/AN/AN/AN/A
OptionableNot OptionableNot OptionableNot OptionableNot OptionableNot Optionable
SourceHeadline
AB Science reports today its annual financials as of 31 December 2020 and provides an update on its activitiesAB Science reports today its annual financials as of 31 December 2020 and provides an update on its activities
finance.yahoo.com - April 30 at 12:48 PM
AB Science today announced that its masitinib Phase 2B/3 study (AB12003) in metastatic castrate-resistant prostate cancer (mCRPC) met its predefined primary endpointAB Science today announced that its masitinib Phase 2B/3 study (AB12003) in metastatic castrate-resistant prostate cancer (mCRPC) met its predefined primary endpoint
finance.yahoo.com - April 29 at 3:57 PM
AB Science and University of Chicago to develop Covid-19 drugsAB Science and University of Chicago to develop Covid-19 drugs
pharmaceutical-technology.com - April 7 at 9:47 AM
AB Science and University of Chicago to conduct Covid-19 treatment researchAB Science and University of Chicago to conduct Covid-19 treatment research
pharmaceutical-business-review.com - April 7 at 9:47 AM
AB Science announces the signing of an exclusive licensing agreement with the University of ...AB Science announces the signing of an exclusive licensing agreement with the University of ...
apnews.com - April 6 at 7:48 AM
AB Science provides an update on the expected timelines for the read-out of its masitinib Phase ...AB Science provides an update on the expected timelines for the read-out of its masitinib Phase ...
apnews.com - March 31 at 1:35 PM
AB Science provides an update on the expected timelines for the read-out of its masitinib Phase 3 study (AB12003) in metastatic castrate-resistant prostate cancerAB Science provides an update on the expected timelines for the read-out of its masitinib Phase 3 study (AB12003) in metastatic castrate-resistant prostate cancer
finance.yahoo.com - March 31 at 1:35 PM
AB Science announces that a new independent publication confirms the role of masitinib as a ...AB Science announces that a new independent publication confirms the role of masitinib as a ...
apnews.com - March 8 at 8:24 AM
AB Science announces that a new independent publication confirms that masitinib has anti-vital ...AB Science announces that a new independent publication confirms that masitinib has anti-vital ...
apnews.com - January 25 at 8:49 AM
AB Sciences Masitinib: An Uncertain Success For Alzheimers DiseaseAB Science's Masitinib: An Uncertain Success For Alzheimer's Disease
seekingalpha.com - December 25 at 1:51 PM
AB Science announces the success of its capital raise for a total amount of 15 million eurosAB Science announces the success of its capital raise for a total amount of 15 million euros
finance.yahoo.com - December 21 at 8:58 AM
AB Science issues a corrective press release regarding adverse events information from study ...AB Science issues a corrective press release regarding adverse events information from study ...
apnews.com - December 18 at 12:38 PM
AB Science communicates the results from phase 2B/3 study evaluating masitinib in Alzheimer’s diseaseAB Science communicates the results from phase 2B/3 study evaluating masitinib in Alzheimer’s disease
finance.yahoo.com - December 18 at 7:37 AM
AB Science announces that Phase 2B/3 study evaluating oral in Alzheimer’s disease met its ...AB Science announces that Phase 2B/3 study evaluating oral in Alzheimer’s disease met its ...
apnews.com - December 17 at 8:19 AM
AB Science issues a corrective press release regarding adverse events information from study AB09004 reported on December 16, 2020AB Science issues a corrective press release regarding adverse events information from study AB09004 reported on December 16, 2020
finance.yahoo.com - December 17 at 8:19 AM
Items Tagged with AB Science SAItems Tagged with 'AB Science SA'
bioworld.com - December 17 at 12:18 AM
AB Science shares rise on preliminary masitinib data in Alzheimer’sAB Science shares rise on preliminary masitinib data in Alzheimer’s
bioworld.com - December 17 at 12:18 AM
AB Science will host a live webcast on December 17, 2020 on masitinib results in Alzheimer’s DiseaseAB Science will host a live webcast on December 17, 2020 on masitinib results in Alzheimer’s Disease
finance.yahoo.com - December 16 at 2:17 PM
AB Science announces that Phase 2B/3 study evaluating oral in Alzheimer’s disease met its primary endpointAB Science announces that Phase 2B/3 study evaluating oral in Alzheimer’s disease met its primary endpoint
finance.yahoo.com - December 16 at 9:12 AM
AB Science will host a live webcast on Friday December 11, 2020 on masitinib’s results in pancreatic cancerAB Science will host a live webcast on Friday December 11, 2020 on masitinib’s results in pancreatic cancer
finance.yahoo.com - December 8 at 5:35 PM
AB Science’s Mastinib Plus Gemcitabine Improves Survival in Early Pancreatic CancerAB Science’s Mastinib Plus Gemcitabine Improves Survival in Early Pancreatic Cancer
pharmalive.com - December 4 at 4:24 PM
AB Science announces that confirmatory Phase 3 study AB12005 with masitinib in first line ...AB Science announces that confirmatory Phase 3 study AB12005 with masitinib in first line ...
apnews.com - December 4 at 4:14 AM
EIB signs €15.0 million financing deal with AB Science to support the development of masitinib as a treatment for COVID-19EIB signs €15.0 million financing deal with AB Science to support the development of masitinib as a treatment for COVID-19
news.europawire.eu - November 30 at 3:29 AM
AB Science announces a financing of 4.5 million euros through the issuance of bonds convertible into new ordinary sharesAB Science announces a financing of 4.5 million euros through the issuance of bonds convertible into new ordinary shares
finance.yahoo.com - October 29 at 4:18 AM
AB Science Presents Phase 2B/3 Study Results in Progressive Multiple Sclerosis at the World's Largest Multiple Sclerosis Research ConferenceAB Science Presents Phase 2B/3 Study Results in Progressive Multiple Sclerosis at the World's Largest Multiple Sclerosis Research Conference
finance.yahoo.com - September 14 at 3:21 AM
DateCompanyBrokerageAction
6/30/20201933 IndustriesCanaccord GenuityDowngrade
12/7/2020AB ScienceHC WainwrightReiterated Rating
(Data available from 5/14/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.